The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer

Overview

Journal J Biomed Biotechnol

Specialty Biology

Date 2011 Jun 2

PMID 21629760

Citations 15

Authors

Mauricio Escobar

Michel Velez

Astrid Belalcazar

Edgardo S Santos

Luis E Raez

Affiliations

Soon will be listed here.

Abstract

Lung cancer therapy with current available chemotherapeutic agents is mainly palliative. For these and other reasons there is now a great interest to find targeted therapies that can be effective not only palliating lung cancer or decreasing treatment-related toxicity, but also giving hope to cure these patients. It is already well known that the ubiquitin-proteasome system like other cellular pathways is critical for the proliferation and survival of cancer cells; thus, proteosome inhibition has become a very attractive anticancer therapy. There are several phase I and phase II clinical trials now in non-small cell lung cancer and small cell lung cancer using this potential target. Most of the trials use bortezomib in combination with chemotherapeutic agents. This paper tends to make a state-of-the-art review based on the available literature regarding the use of bortezomib as a single agent or in combination with chemotherapy in patients with lung cancer.

Citing Articles

Chemical Proteomics Reveals that the Anticancer Drug Everolimus Affects the Ubiquitin-Proteasome System.

Lobas A, Saei A, Lyu H, Zubarev R, Gorshkov M ACS Pharmacol Transl Sci. 2024; 7(3):787-796.

PMID: 38481686 PMC: 10928898. DOI: 10.1021/acsptsci.3c00316.

Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.

Kanbur E, Baykal A, Yerlikaya A Med Oncol. 2021; 38(9):112.

PMID: 34363546 DOI: 10.1007/s12032-021-01563-1.

Explaining the Genetic Causality for Complex Phenotype via Deep Association Kernel Learning.

Bao F, Deng Y, Du M, Ren Z, Wan S, Liang K Patterns (N Y). 2020; 1(6):100057.

PMID: 33205126 PMC: 7660384. DOI: 10.1016/j.patter.2020.100057.

An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line.

Yerlikaya A, Okur E Cytotechnology. 2019; 72(1):121-130.

PMID: 31863311 PMC: 7002631. DOI: 10.1007/s10616-019-00362-x.

Impact of viral presence in tumor on gene expression in non-small cell lung cancer.

Kim Y, Pierce C, Robinson L BMC Cancer. 2018; 18(1):843.

PMID: 30134863 PMC: 6106745. DOI: 10.1186/s12885-018-4748-0.

References

Ling Y, Liebes L, Jiang J, Holland J, Elliott P, Adams J . Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003; 9(3):1145-54. View

Aghajanian C, Soignet S, Dizon D, Pien C, Adams J, Elliott P . A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002; 8(8):2505-11. View

Ling Y, Liebes L, Zou Y, Perez-Soler R . Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 2003; 278(36):33714-23. DOI: 10.1074/jbc.M302559200. View

Lara Jr P, Koczywas M, Quinn D, Lenz H, Davies A, Lau D . Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2007; 1(2):126-34. View

Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey D . Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2003; 2(9):835-43. View

Frankel A, Man S, Elliott P, Adams J, Kerbel R . Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 2000; 6(9):3719-28. View

Moore B, Eustaquio A, McGlinchey R . Advances in and applications of proteasome inhibitors. Curr Opin Chem Biol. 2008; 12(4):434-40. PMC: 2560982. DOI: 10.1016/j.cbpa.2008.06.033. View

Davies A, Ruel C, Lara P, Lau D, Gumerlock P, Bold R . The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008; 3(1):68-74. DOI: 10.1097/JTO.0b013e31815e8b88. View

Teicher B, Ara G, Herbst R, Palombella V, Adams J . The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999; 5(9):2638-45. View

10.

Scagliotti G, Germonpre P, Bosquee L, Vansteenkiste J, Gervais R, Planchard D . A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer. 2009; 68(3):420-6. DOI: 10.1016/j.lungcan.2009.07.011. View

11.

Schenkein D . Use of proteasome inhibition in the treatment of lung cancer. Clin Lung Cancer. 2005; 6 Suppl 2:S89-96. DOI: 10.3816/clc.2004.s.021. View

12.

Pham L, Tamayo A, Yoshimura L, Lo P, Ford R . Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003; 171(1):88-95. DOI: 10.4049/jimmunol.171.1.88. View

13.

Zhang H, Wang J, Yang X, Hsu H, Mountz J . Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene. 2004; 23(11):2009-15. DOI: 10.1038/sj.onc.1207373. View

14.

Mortenson M, Schlieman M, Virudachalam S, Bold R . Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol. 2004; 54(4):343-53. DOI: 10.1007/s00280-004-0811-4. View

15.

Sorokin A, Kim E, Ovchinnikov L . Proteasome system of protein degradation and processing. Biochemistry (Mosc). 2010; 74(13):1411-42. DOI: 10.1134/s000629790913001x. View

16.

Lynch T, Fenton D, Hirsh V, Bodkin D, Middleman E, Chiappori A . A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2009; 4(8):1002-9. DOI: 10.1097/JTO.0b013e3181aba89f. View

17.

Bold R, Virudachalam S, McConkey D . Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res. 2001; 100(1):11-7. DOI: 10.1006/jsre.2001.6194. View

18.

Ludwig H, Khayat D, Giaccone G, Facon T . Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005; 104(9):1794-807. DOI: 10.1002/cncr.21414. View

19.

Edelman M, Burrows W, Krasna M, Bedor M, Smith R, Suntharalingam M . Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer. Lung Cancer. 2009; 68(1):84-8. DOI: 10.1016/j.lungcan.2009.05.003. View

20.

Denlinger C, Rundall B, Keller M, Jones D . Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg. 2004; 78(4):1207-14. DOI: 10.1016/j.athoracsur.2004.04.029. View